Sign inJoin waitlistJoin the waitlist

Colin Dinney

Urology

Credentials: · ·

History

Urology
1989–1994
UNIV OF MANITOBA, WINNIPEG
1978–1982

Research

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy
Cancer Cell · 2014 · 1,404 citations
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
European Urology · 2020 · 1,071 citations
Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
Clinical Cancer Research · 1999 · Last of 8 authors · 507 citations

Ashish Kamat
161 papers · 1 as a resident
HG
Herbert Grossman
100 papers
Bogdan Czerniak
68 papers
Neema Navai
65 papers · 3 as a fellow
Arlene Siefker-Radtke
53 papers
Charles Guo
44 papers
PB
Peter Black
42 papers · 20 as a resident
SL
Seth Lerner
40 papers
Robert Svatek
36 papers · 21 as a fellow
Louis Pisters
30 papers
Surena Matin
30 papers
Yair Lotan
30 papers

Grants

Mechanisms of Bladder Cancer Development and Its Therapeutic Vulnerabilities to Preventive and Interventive Therapy.
National Cancer Institute · P01
Project lead · $809.1K · University of Tx Md Anderson Can Ctr
2025–2030
Rigorous and Reproducible Mutational Analysis of the Urinary Exosomal DNA
National Cancer Institute · R01
PI · $3.1M · University of Tx Md Anderson Can Ctr
2019–2025
SPORE in Genitourinary Cancer
National Cancer Institute · P50
Contact PI · $37.4M · University of Tx Md Anderson Can Ctr
2001–2019
Biology of Bladder Cancer Metastases
National Cancer Institute · R29
Contact PI · $513.2K · University of Tx Md Anderson Can Ctr
1996–2001

Clinical trials

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
Study chair · Completed · Phase 2
FKD Therapies Oy
2012–2016
1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer
Study chair · Completed · Phase 1
M.D. Anderson Cancer Center
2011–2016
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
Study chair · Completed · Phase 2
M.D. Anderson Cancer Center
2001–2006
AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
Study chair · Completed · Phase 2
Anthra Pharmaceuticals
1998–2002